Table 4 mRNA expression level, from highest to lowest, of selected hTAS2R in various cancers and their matched controls

Breast cancer (assessed using qRT-PCR)

hTAS2R1

Non-cancerous mammary epithelial cell line MCF-10A (1)

vs

Highly metastatic breast cancer cell line MDA-MB-231 (2) and poorly metastatic cell line MCF-7 (3)

(2) > (1)

[239]

(3) > (2) > (1)

[238]

hTAS2R3

(2) > (1)

[239]

hTAS2R4

(1) > (2)

[239]

(1) > (2) > (3)

 < 0.001

[238]

hTAS2R5

(1) > (2)

[239]

hTAS2R7

(2) > (1)

[239]

hTAS2R8

(2) > (1)

[239]

hTAS2R9

(1) ~ (2)

[239]

hTAS2R10

(2) > (1)

[239]

(1) > (2) > (3)

[238]

hTAS2R13

(2) > (1)

[239]

hTAS2R14

(2) > (1)

 < 0.001

[239]

hTAS2R16

(1) ~ (1)

[239]

hTAS2R19

(2) > (1)

[239]

hTAS2R20

(2) > (1)

 < 0.01

[239]

hTAS2R38

(2) > (1)

[239]

(3) > (1) > (2)

[238]

hTAS2R39

(2) > (1)

[239]

hTAS2R40

(2) > (1)

[239]

hTAS2R41

(1) > (2)

[239]

hTAS2R42

(1) ~ (2)

[239]

hTAS2R30/31/43/45/46

(2) > (1)

0.001

[239]

hTAS2R49

(2) > (3) > (1)

[238]

hTAS2R50

(2) > (1)

[239]

hTAS2R60

(2) > (1)

[239]

Ovarian cancer (assessed using qRT-PCR)

hTAS2R1

A:

Normal fallopian tube tissue (1)

vs

High-grade serous human ovarian cancer cell line OVCAR4 (2), OVCAR8 (3) and Ovarian papillary cystadenocarcinoma tissue (4)

B:

Normal uterine tissue (5)

vs

Clear cell human ovarian cancer line SKOV3 (6), Hypermutated IGROV1 human ovarian cancer cell line (7) and Uterine/endometrial adenocarcinoma cell line HEC1a (8)

A: (4) > (1) > (3) > (2)

B: (3) > (1) > (2) > (4)

 < 0.05 for (3)

 < 0.05 for (4)

[241]

hTAS2R4

A: (2) > (4) > (1) > (3)

B: (1) > (3) > (2) > (4)

 < 0.05 for (3)

 < 0.05 for (2)

[241]

hTAS2R10

A: (2) > (3) > (4) > (1)

B: (3) > (4) > (1) > (2)

 < 0.01 for (4)

[241]

hTAS2R14

A: (1) > (2) > (3) > (4)

B: (1) > (3) > (2) > (4)

 < 0.05 for (3);

 < 0.001 for (4)

 < 0.01 for (2); < 0.05 for (4)

[241]

hTAS2R38

A: (1) > (2) ~ (3) > (4)

B: (1) > (4) > (2) > (3)

 < 0.0001 for (2), (3) and (4)

 < 0.0001 for (2) and (3);

 < 0.001 for (4)

[241]

Prostate cancer (assessed using qRT-PCR)

hTAS2R1

Benign prostatic hyperplasia cell line BPH1 (1)

vs

Human prostate cancer cell line PC3 (2),

LNCAP (3)

and

DU145 (4)

(1) > (2) > (3) > (4)

 < 0.05 for (2);

 < 0.01 for (3); < 0.0001 for (4);

[241]

hTAS2R4

(1) > (3) > (2) > (4)

 < 0.001 for (2); < 0.05 for (3); < 0.0001 for (4)

[241]

hTAS2R10

(1) > (4) > (2) > (3)

 < 0.01 for (2);

 < 0.001 for (3)

[241]

hTAS2R14

(1) > (3) > (4) > (2)

 < 0.001 for (2) and (4);

 < 0.01 for (3)

[241]

hTAS2R38

(1) > (2) > (3) > (4)

 < 0.05 for (3);

 < 0.0001 for (4);

[241]

Pancreatic cancer (assessed using qRT-PCR)

hTAS2R10

Human pancreatic cell line PANC-1 highly resistant to gemcitabine (1)

vs

Human pancreatic cell line BxPC3; more sensitive to gemcitabine (2)

(2) > (1)

–

[244]

Neuroblastoma (assessed using qRT-PCR)

hTAS2R8

More differentiated N-type NB cell line SY5Y (1)

vs

More malignant and less differentiated I-type NB cell line BE(2)C (2)

(1) > (2)

 < 0.05

[199]

hTAS2R10

(1) > (2)

 < 0.05

[199]

Acute myeloid leukaemia (assessed using qRT-PCR)

hTAS2R1

Primary AML cells (1)

vs

Human leukaemia cell line OCI-AML3 (2) and Human leukaemia cell line THP-1 (3)

(1) > (2) > (3)

 < 0.05

[255]

hTAS2R3

(3) > (2) > (1)

 < 0.05

hTAS2R4

(2) > (1) > (3)

 < 0.05

hTAS2R5

(1) > (3) > (2)

 < 0.05

hTAS2R7

(3) > (1) > (2)

 < 0.05

hTAS2R8

(1) > (2) > (3)

 < 0.05

hTAS2R9

(3) > (1) > (2)

 < 0.05

hTAS2R10

(1) > (3) > (2)

 < 0.05

hTAS2R13

(3) > (1) > (2)

 < 0.05

hTAS2R14

(2) > (3) > (1)

 < 0.05

hTAS2R16

(1)

 < 0.05

hTAS2R20

(3) > (1) > (2)

 < 0.05

hTAS2R30/47

(1) > (3) > (2)

 < 0.05

hTAS2R31

(3) > (2) > (1)

 < 0.05

hTAS2R38

(1) > (3) > (2)

 < 0.05

hTAS2R39

(1) > (2)

 < 0.05

hTAS2R40

(3) > (1)

 < 0.05

hTAS2R41

(1) > (3) > (2)

 < 0.05

hTAS2R43

(1) > (3)

 < 0.05

hTAS2R46

(1) > (3)

 < 0.05

hTAS2R50

(1) > (3) > (2)

 < 0.05